Literature DB >> 13680216

Interferons in enteroviral heart disease: modulation of cytokine expression and antiviral activity.

Albert Heim1, Sabine Weiss.   

Abstract

Interferon (IFN)-beta has a more than 120-fold higher antiviral activity than the closely related IFN-alpha in human myocardial fibroblasts infected with the cardiotropic enterovirus coxsackievirus B3 (CVB3). CVB3 replication induces interleukin (IL)-6 and IL-8 expression in myocardial fibroblasts, and suppresses the expression of monocyte chemoattractant protein-1 (MCP-1). We investigated whether the higher antiviral activity of IFN-beta compared to IFN-alpha was a result of a suppression of IL-8 expression by IFN-beta since previous studies had indicated that IL-8 stimulates enterovirus replication. Human myocardial fibroblasts were treated with either IFN-alpha, IFN-beta or IFN-gamma (0, 10, 100, or 1,000 IU/ml) and the concentrations of IL-6, IL-8 and MCP-1 were measured in culture supernatants by immunoassays. Both IFN-beta and IFN-gamma reduced IL-6 and IL-8 expression significantly. In addition, neutralization of IL-8 in culture supernatants of myocardial fibroblasts using a monoclonal antibody demonstrated a significant reduction of CVB3 titers. Antiproliferative effects of all three IFNs were very low (<30% with 1,000 IU/ml), indicating that the suppression IL-6 and IL-8 was not related to cytotoxicity. MCP-1 expression was increased only by high concentrations of IFN-gamma (1,000 IU/ml). By contrast, IFN-alpha had no significant effect on IL-6, IL-8 and MCP-1 expression. In conclusion, suppression of IL-8 expression is an "immuno-modulating" feature of IFN-beta in human myocardial fibroblasts, which is similar to the activity of IFN-gamma. This feature of IFN-beta contributes to its high antiviral activity against CVB3 and may be useful in the treatment of enteroviral heart disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13680216     DOI: 10.1007/s00430-003-0200-3

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  43 in total

1.  Enterovirus-induced production of pro-inflammatory and T-helper cytokines by human leukocytes.

Authors:  G R Vreugdenhil; P G Wijnands; M G Netea; J W van der Meer; W J Melchers; J M Galama
Journal:  Cytokine       Date:  2000-12       Impact factor: 3.861

2.  Interferon-gamma induces AT(2) receptor expression in fibroblasts by Jak/STAT pathway and interferon regulatory factor-1.

Authors:  M Horiuchi; W Hayashida; M Akishita; S Yamada; J Y Lehtonen; K Tamura; L Daviet; Y E Chen; M Hamai; T X Cui; M Iwai; Y Minokoshi
Journal:  Circ Res       Date:  2000-02-04       Impact factor: 17.367

Review 3.  Antiviral actions of interferons.

Authors:  C E Samuel
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

4.  Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers.

Authors:  P Salmon; J Y Le Cotonnec; A Galazka; A Abdul-Ahad; A Darragh
Journal:  J Interferon Cytokine Res       Date:  1996-10       Impact factor: 2.607

5.  Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma.

Authors:  G Fierlbeck; A Ulmer; T Schreiner; W Stroebel; U Schiebel; J Brzoska
Journal:  J Interferon Cytokine Res       Date:  1996-10       Impact factor: 2.607

6.  Transient induction of cytokine production in human myocardial fibroblasts by coxsackievirus B3.

Authors:  A Heim; S Zeuke; S Weiss; W Ruschewski; I M Grumbach
Journal:  Circ Res       Date:  2000-04-14       Impact factor: 17.367

7.  Transcriptional inhibition of the interleukin-8 gene by interferon is mediated by the NF-kappa B site.

Authors:  I C Oliveira; N Mukaida; K Matsushima; J Vilcek
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

8.  Cardiodepressant effects of interferon-gamma and endotoxin reversed by inhibition of NO synthase 2 in rat myocardium.

Authors:  X Sun; L M Delbridge; G J Dusting
Journal:  J Mol Cell Cardiol       Date:  1998-05       Impact factor: 5.000

9.  Cultured human myocardial fibroblasts of pediatric origin: natural human interferon-alpha is more effective than recombinant interferon-alpha 2a in carrier-state coxsackievirus B3 replication.

Authors:  A Heim; C Brehm; M Stille-Siegener; G Müller; S Hake; R Kandolf; H R Figulla
Journal:  J Mol Cell Cardiol       Date:  1995-10       Impact factor: 5.000

10.  Subclassification of dilated cardiomyopathy and interferon treatment.

Authors:  M Stille-Siegener; A Heim; H R Figulla
Journal:  Eur Heart J       Date:  1995-12       Impact factor: 29.983

View more
  4 in total

1.  Induction of a broad spectrum of inflammation-related genes by Coxsackievirus B3 requires Interleukin-1 signaling.

Authors:  Fabienne Rehren; Barbara Ritter; Oliver Dittrich-Breiholz; Andreas Henke; Elena Lam; Semra Kati; Michael Kracht; Albert Heim
Journal:  Med Microbiol Immunol       Date:  2012-06-03       Impact factor: 3.402

2.  IFN-alpha expression and antiviral effects are subtype and cell type specific in the cardiac response to viral infection.

Authors:  Lianna Li; Barbara Sherry
Journal:  Virology       Date:  2009-11-06       Impact factor: 3.616

3.  Over-expression of mitochondrial antiviral signaling protein inhibits coxsackievirus B3 infection by enhancing type-I interferons production.

Authors:  Qing-Meng Zhang; Wu-Qi Song; Yu-Jun Li; Jun Qian; Ai-Xia Zhai; Jing Wu; Ai-Mei Li; Jun-Ming He; Jin-Yun Zhao; Xin Yu; Lan-Lan Wei; Feng-Min Zhang
Journal:  Virol J       Date:  2012-12-19       Impact factor: 4.099

4.  c-FLIP-Short reduces type I interferon production and increases viremia with coxsackievirus B3.

Authors:  Iwona A Buskiewicz; Andreas Koenig; Brian Roberts; Jennifer Russell; Cuixia Shi; Sun-Hwa Lee; Jae U Jung; Sally A Huber; Ralph C Budd
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.